Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MDX2004 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on MDX2004, a putative trispecific antibody–fusion protein targeting CD3, CD28, and TNFRSF9 (4-1BB) (Sep 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MDX2004 | MDX-2004|MDX 2004 | CD28 Antibody 12 CD3 Antibody 120 TNFRSF9 Antibody 36 | Limited information is currently available on MDX2004, a putative trispecific antibody–fusion protein targeting CD3, CD28, and TNFRSF9 (4-1BB) (Sep 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07110584 | Phase Ib/II | MDX2004 | Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors | Recruiting | ISR | AUS | 0 |